Therapy Detail

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Therapy Name Linvoseltamab
Synonyms
Therapy Description

Lynozyfic (linvoseltamab) is a bispecific antibody that binds to TNFRSF17 (BCMA) and CD3 with potential antitumor activity (Blood (2019) 134 (Supplement_1): 3176). Lynozyfic (linvoseltamab) is FDA-approved for use in patients with previously-treated relapsed or refractory multiple myeloma (FDA.gov).

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Linvoseltamab Lynozyfic REGN5458|REGN-5458|REGN 5458|Anti-BCMA/CD3 BiTE|linvoseltamab-gcpt CD3 Antibody 119 TNFRSF17 Antibody 22 Lynozyfic (linvoseltamab) is a bispecific antibody that binds to TNFRSF17 (BCMA) and CD3 with potential antitumor activity (Blood (2019) 134 (Supplement_1): 3176). Lynozyfic (linvoseltamab) is FDA-approved for use in patients with previously-treated relapsed or refractory multiple myeloma (FDA.gov).

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT03761108 Phase Ib/II Linvoseltamab First in Human (FIH) Study of REGN5458 in Patients With Relapsed or Refractory Multiple Myeloma Recruiting USA | GBR | ESP | DEU | BEL 2
NCT05730036 Phase III Linvoseltamab Dexamethasone + Elotuzumab + Pomalidomide A Study to Learn How Linvoseltamab (REGN5458) Will Work Compared to the Elotuzumab, Pomalidomide and Dexamethasone (EPd) Combination, in Participants With Relapsed/Refractory Multiple Myeloma (LINKER-MM3) Recruiting USA | POL | NLD | ITA | ISR | GBR | FRA | ESP | DEU | CAN | BRA | BEL | AUS 5
NCT07009899 Phase II Linvoseltamab BCMA Bispecific Antibody Therapy for Post-BCMA CAR T-Cell Therapy Relapse (RECLAIM) (RECLAIM) Not yet recruiting USA 0
NCT05828511 Phase Ib/II Linvoseltamab A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment. (LINKER-MM4) Recruiting USA | FRA | ESP 0
NCT05955508 Phase II Linvoseltamab A Proof-of-Concept Trial to Study the Safety and Activity of Linvoseltamab in Participants With Smoldering Multiple Myeloma at High Risk of Developing Multiple Myeloma Recruiting ESP 0
NCT06140524 Phase II Linvoseltamab A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma (LINKER-MGUS1) Recruiting USA | ESP 0
NCT06376526 Phase II Linvoseltamab IMMUNOPLANT for Newly Diagnosed Multiple Myeloma (IMMUNOPLANT) Recruiting USA 0
NCT06669247 Phase Ib/II Linvoseltamab Linvoseltamab + REGN7945 A Study to Assess the Safety and Anti-Tumor Activity of REGN7945 in Combination With Linvoseltamab in Adult Participants With Relapsed/Refractory Multiple Myeloma (COSTIMM) Recruiting GBR | AUS 0
NCT07181941 Phase Ib/II Linvoseltamab Response-Based Dose Reduction of Linvoseltamab in the Treatment of Relapsed, Refractory, or Triple-Class Relapsed/Refractory Multiple Myeloma Not yet recruiting USA 0


Additional content available in Icon for CKB-BoostCKB BOOST